A major new systematic review has concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental
Welcome to Business of Cannabis’ new research digest, unpacking the latest clinical evidence shaping cannabis therapeutics. While headlines often focus
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled
We won’t spam you
